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This highly regarded organization is one of the few engaged in
contraceptive research and development ;hat focuses on  the
needs  of the developing  world. The Special  Programme of
Research, Development and Research Training in Human Re-
production (HRP) merits the Bank's continued and expanded
support.
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Population,  Health,  and Nutrition
Thispaper--  a product of the Population, iealth and Nutrition Division, Population and luman  Resources
Dcpaiiment --  is pail of a larger effort in PRE to providc informationi  on1  activities in population, health,
and niutrition assisted by the Bank under its Special Grants Program.  Special Grants Programs support
multi-countr., activitics, complementing the Batik's direct lending operations.  Copies arc available frcc
from thc World Bank. 1818 H Street NW, W'ashinrg  ton DC 2('433. Plcase contact Otilia Nadora, room S6-
065, extension 31019 (13 pages).  October 1991.
rhe  Special Programmin  of Rescarcihl Dccvlop-  onl)  impact, in many areas (such as coordinating
ment and Research Training in Hluman  Repro-  world rcsearch efforts and developing new
duction (HRP) - which began as a special  metihods  for regulating fertility).
prog ram ol thc World Hcalth Organization --  is
onc o' the few organizations engageds  in contra-  TIhc Bank's cosponsorshiip of HRP has
ceptive research and development that Iocu;cs  strengthened the program's; links with govern-
on thc  needs of thei  developing world.  ments  and facilitated its access  to ministries
outside the health field.  The Bank's rolc is
Nassim reviews the factors that lcd thc  important to policy coordinationi  and to sustain-
World Bank to begin providing the organization  ing donor commitinent to the program.
with fi  nmcial  supporl iT)  FY88 and examines the
program's  accomplishil,  .nts  and presenl direc-  The Bank's commitment of $2 million a year
ion.  represents 10 perc,cnt  of HRP's tota1  fundinig.
IIRP has gain'  inticniational  rcspect, and its
MNajor  evaluations ot HiRP  strongl1 cndorse  iolid record o  achievemtii  justify the Banik's
the program, concluding that thc program has  conitn1iued - anid  expanided - support.
h3ad  a major impact - thi  principal. it not the
111i  I'R  L rkOnTIt011;'  SCII'I  JK;i.1  -OnnIIcs  die Fi.  r:i'  -*  utr  ii  \  .Im  \\j\  ji  Oin  l'Oi  P\.  RcLarTl i. and F \Etr,lma
Aff,.irsCo'nplkcx  pnihch  jd eo! IL Rcric i  . I  C1  r'l  > .UI 4uIk.  . *\ cn  I  nIdtIt;  1 '  I  X',l  xl.  .
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IN HUMAN REPRODUCTION (HRP)
Cosponsored by UNDP/UNF.2AIWHO/WORLD  BANK
1.  The Special Programme of Research,  Development and Research Training  in Human Reproduction is
one of the few organizations engaged in contraceptive research and development that focusses on the needs of
the developing world.  Its scope has widened since its inception to include broader issues of reproductive health,
and it has recently  increased attention to develoving national capacity to identify and address country needs.
The establishment of a worldwide network of centers collaborating in research, simultaneously contributing to
fertility research and institutional development; documentation of the risks and benefits of developing country
use of the most widely available contraceptives; and the introduction of two new contraceptive methods, have
been its main achievements  to date.  This paper provides a brief overview of the factors which led the World
Bank to begin providing financial support in FY1988, and of the progam's  accomplishments and present
directions.
BACKGROUND
2.  HRP was established in  1972 as a  Special Program of the World Health Organization (WHO) with a
uuate.4  "'t  picuinote, coordinate, support, conduct and evaluate rescarch or, humLanL  reproductiorn, with
particular reference to the needs of developing countries".  Funding came mainly from European donors and the
United  Nations Population  Fund (UNFPA).  The World Bank was involved in an advisory capacity.
3.  The World Bank's decision to provide financial support to the program resulted from concern over
adverse changes in the financial, political and legal environment of reproductive research in the  1980s. The
grounds for concern were  summed up by World Bank managemen' in this way:  "The combination of increased
need and reduced prospects of an appropriate response to that need by the existing mechanisrris amounts to a
potential crisis  that could, unless corrective action is taken, eventually threaten the effectiveness of population
policies and the success of  family planning programs in the developing countries.  ....  the present technological2
base is inadequate  to attract the hundreds  of millions  of new couples  that must use contraception  if fertility
levels in developing  countries  are to be reduced  to approximately  those prevailing  in most industrialized
countries."'  These conclusions  were based on the following  factors:
*  declining  funding  for contraceptive  research  and development,  (amounting  to a 20 percent
reduction  in real terms between 1975  and 1983), mainly  the result of industry  withdrawal  from
the field due to product liability  concerns,  and dissatisfaction  with the restrictive  and prolonged
regulatory  approval  process
*  concern about the repercussions  of the adverse  developments  in the U.S., the source at the
time of 75 percent of worldwide  funding. For example, the greatly  increased  cost of insurance
following  a successful  liability  suit against  one company  caused the withdrawal  of all but one
IUD from the U.S. market, a move that could be, and indeed was, interpreted  in many parts
of the world as a judgement on the safety of all IUDs, rather than as the commercial  decision
it was in most cases
- the need to develop  a wider range of contraceptive  methods, in particular  those potentially
more appropriate  and acceptable  to developing  country  users--for  example, longer acting  or
cheaper methods, male methods,  and methods  less dependent  on well developed  health  systems
for their delivery
the need for safe, effective  methods,  adequately  tested under developing  country  conditions
- concern  at rapid population  growth and recognition  that a wider range of contraceptive
methods  is generally  associated  with increased  contraceptive  use
*  the need for an organization  that could coordinate  all the complex  steps and different  agencies
involved  in the process of bringing  a contraceptive  from the point of an idea, to use:  the work
of basic research; testing and development  to the point  of production;  guiding  the product
through the trials necessary  for regulatory  approval;  manufacturing  and packaging  the drug or
device; marketing  it, and finally, conducting  post-marketing  surveillance
the need for leadership  in the field from an organization  which  would receive  widespread
support, both financial  and political,  given the increasingly  controversial  nature of
contraceptive  research
4.  HRP's emerging  preeminence  in the field, and, in particular,  its emphasis  on the needs  of the developing
world, made it the logical choice  to lead a new international  initiative. However, its status as a program within
WHO and responsible  only to it, aroused concern  that it would  not attract the necessary  suipport. The Bank
' Memo  of October 14, 1986,  from Mr. John  North, Director,  PHND, to Mr. Ernest  Stern,  SVPOP,  through
Mr. S. Shahid  Husain  VPOPS.3
engaged  in extensive  discussions  with other agencies  of the U.N. system, with donor governments,  and with
many of the other organizations  active in the field of international  family  planning  and contraceptive  research,
and it was decided to restructure  HRP along lines similar to the Tropical Diseases  Research (TDR) Programme.
Following this agreement,  the World Bank  joined with WHO, the United Nations  Development  Progamnme
(UNDP), and the United Nations Population  Fund in becoming  co-sponsors  of the program, with WHO as the
Executing  Agency.
PROGRAM  ORGANIZATION
5.  HRP carries out two inter-dependent  types of operation  in fulfilling  its mandate: first, the coordination  of
a worldwide  research and development  effort in fertility  regulation,  and second, the strengthering  of developing
countries' national capacity  and resources  for research  in reproductive  health.  The first type of operation  is the
responsibility  of the Research  and Development  component  of the Special Programme,  the second  the
responsibility  of the Resources  for Research  component. Administrative  responsibility,  with technical  support,
is vested in a Secretariat  under the Director of the Programme. The program receives  scientific  review  and
evaluation  from the Scientific  And Technical  Advisory  Group (STAG),  a committee  of independent  experts in
the field of reproductive  research. Policy is the responsibility  of the Policy and Coordination  Committee
(PCC), the governing  body of HRP. Its 32 members, most of whom represent  developing  country
govemments, meet at least once a year.  The Bank is a member  of the PCC, as are the other co-sponsors. A
sub-group  of this committee,  the Standing  Comrnittee,  comprised  only of the co-sponsors,  meets three to four
times a year to provide more continuous  program oversight  and direction. This organizational  structure  is
presented  in Figure 1.
6.  Research and Development.  Research  and development  activities  are conducted  through  Task Forces,
each with a specific focus.  The Task Forces change  over time as different  needs take priority. There are
currently  eight, (shown in Figure 1), each advised  and directed by a Steering  Committee. Their activities  fall4
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Figure 1.  Governing  and advisory  bodies  of the Programme.
Source:  WHO.  1990.  Research in Human Reproduction: Biennial Report 1988-89.  Special Programme  of
Research,  Development  and Research  Training  in Human Reproduction,  Geneva.5
under the following main headings:  evaluadon of the safety and efficacy of existing methods of fertility regulation;
development of new and  improved  methods, and  research into the behavioral and social  aspects of  reproductive
behavior,  as well as investigation of the extent and causes of infertility.
7.  In addition to the overall scientific direction provided by STAG, the research and  development program  is
guided  by scientific and  technical review  committees,  and  by expelts  callod  ill foi  ad  hoc  consultations.  The
program  makes a  special effort  to include  scientists from  developing countries and  women  scientists  in all  the
advisory committees.  Stringent ethical standards are set and promoted by the program - essential in work that often
involves human subjects, and in the sensitive area of human reproduction research especially.  The Scientific and
Ethical  Review Group provides an  independent ethical and  technical assessment  of all Task  Force projects,  and
research proposals.  The Toxicology Group reviews projects involving the use of new drugs and devices in human
subjects, and the Steering Committees review all projects in their Task Force area.  All projects submitted to the
program must show evidence of approval by institutional and national ethical review mechanisms. (This requirement
has often led to the establishment and strengthening of these ethical review committees).  In addition, projects which
involve human subjects must be approved by a special WHO ethical reivew committee to ensure that such projects
comply with WHO requirements.
8.  Resources for Research.  The strengtliening of national research capabilities has two objectives:  to involve
developing  country research  institutions and  scientists in  the world-wide  research  effort;  and  to help countries
address their own research needs.  The Comrmittee  on Resources for Research oversees  this program  component,
and  individual program  staff  scientists have  responsibility  for  managing  and  coordinating activities  which  are
organized  by geographic region.
9.  Progiram Evaluation.  The program  has  establisb-4  procedures  for  internal and  external  evaluation.  The
scientific committees provide regular  wvaluations  of program activities, and the STAG carries out periodic in-depth
reviews of different program components.  The Director-General  of WHO submits progress reports on HRP to the6
WHO Executive Board, and  to the World Health Assembly.  Three  maj( r external reviews of the program  have
taken place.  The most  recent,  which  focused on  the program's  impact in developing countries,  is discussed  i4
paragraph 22 below.  This sytem of scientific, technical and ethical review has assured HRP's  scientific quality and
credibility.
PROGRAM ACTIVITIES AND ACCOMPLISHMENTS
10.  HRP has a substantial record of success.  One of its greatest contributions has been its strengthening of the
capacity  of developing  country institutions  to participate  in the research  and development  effort, by drawing  them
into a worldwide  network of  centers  that collaborate  in the work of the  Task  Forces.  Centers participating in
multicenter  studies  use  standardized  protocols  and  materials,  with  benefits  to  both  the  institution  and  the
program--increased technical expertise in the country,  and increased confidence in the results of program  studies.
There  are now collaborating centers in 26 developed and 54 developing countries, a significant achievement.
11.  In Research  and Development,  the program's emphasis  on meeting the needs of the developing  world has
resulted  in priority being  given to evaluating  the safety and performance  of currently  available  methods  which  were,
for the most part, developed  and tested in industrialized  settings, and, in the development  of new methods, to
research on methods at an advanced  stage of development  rather than those at an early or exploratory  stage of
investigation. In the area of reproductive  behavior, increasing  attention  is being paid to maternal  health and to
sexually-transmnitted  disease-AIDS  in particular.  These  latter  issues are  also  becoming  very  important  in the
R..sources for Research component where recently HRP has reoriented its efforts in order  to be more responsive
to developing country needs in reproductive health in general, while maintaining its activities in the field of fertility
regulation.7
Research  and Development  Activities
12. Safety  and Efficacy. More women  use contraceptives  than any other  category  of drug or medical  device,  and
many use them for long  periods of time.  It is, therefore, particularly  important  for information  on the safety and
side-effects  of different  contraceptives  to be as complete  and accurate  as possible. Much  of the existing  information
has been collected from the most developed countries. Relatively  little has been obtained from less developed
countries,  even though  the use of contraceptives  in the developing  world  is increasing  on a wide scale. In particular,
not much is known about the safety of contraceptives  when used by women with diseases  which are endemic  in
developing  countries,  and whether  results  from studies  conducted  in developed  coun'ries fre applicable  to other parts
of the world where patterns  of disease  may be very different.
13.  An important  achievement  has neen the publication  of the first series of results from the large, multicenter
study on oral contraceptive  use and cancer.  The results obtained  do not differ markedly  from earlier findings in
North America  and Europe, and confirm the safety  of oral ceontraception  for most women. Oral contraceptive  use
provides some protection  against endometrial  and ovarian cancer.  There is a weak association  with a somewhat
elevated  risk of breast cancer and cervical  cancer but it is not determined  whether the association  is of a causal
nature. No link was found between  oral contraceptives  and liver cancer in developing  countries. Studies  on cancer
and the use  of the injectable  contraceptive  depot-medroxyprogesterone  acetate  (DMPA),  about to be published,  have
helped to quiet the understandable  concern  that  had arisen  over the use of this method  of contraception  in  developing
countries  when the Food  and Drug  Administration  had withheld  approval  for its use  as a contraceptive  in the United
States.
14.  Several other major multinational  safety evaluations  are underway. Among them are a 20-center, four-year
study on how the use of low dose hormonal  contraceptive  pills affects the risk of cardiovascular  disease. Priority
is also being given to studies  on:  the interaction  between  different methods  of contraception  and iron-deficiency
anermia-a  very common  condition  among women of reproductive  age in a large number  of developing  countries;8
the safety of oral contraceptives for women who are chronic carriers of the hepatitis B virus; the safety of different
contraceptives  for  nursing  mothers;  the  long-term  safety  and  efticacy  of  the  widely  used  opper-containing
intrauterine devices; improving the safety of sterilization procedures; the safety of the NORPLANT contraceptive
implant, and the complex problems posed by contraception and  HIV infection.
15.  New and  Improved  Methods.  Research into new methods of fertility  regulation has concentrated  on the
development of  methods critically needed in the developing world--long-acting systemic methods, vaccines,  male
methods and post-ovulatory  methods.  Great progress has been made with two female methods which have been
brought  to  the stage of  large-scale  introduction.  These  methods are  a  once-a-month injectable,  and  a  steroid-
producing vaginal ring.  In fact, two once-a-month injectable preparations have been produced,  and bo.h offer an
alternative to the three-monthly  injectables which, while proven to carry no major health  risk, disrupt menstrual
patterns  in a  way that  makes them  unacceptable  to  many women.  A  great  deal of  work has  gone  into  the
development of a  birth-control  vaccine, and  early trials have proven so encouraging  that a  prototype  vaccine is
nearing the stage of trials with women volunteers.  HRP has continued to assess the efficacy and safety of the new
non-surgical  approach  to early  pregnancy termination,  involving  the use  of  a  combination reg;nen  of  an  anti-
progestin, mifepristone (often known as RU486),  and a prostaglandin.  Regulatory approval has been granted in
France and Great  Britain.  Success with male methods is further away but some progress is being made.  Promnising
results from the first clinical trial of male hormonal contraception have recently been published. A non-surgical and
potentially reversible method of  male sterilization is being pursued.
16.  Infertility.  HRP has been one of the foremost agencies investigating the causes and incidence of infertility.
It has already established that infertility is a condition that affects some 35 to 70 million  mr.arried  couples around
the world,  and  that a  principal cause,  particularly  in women,  is infection as  a  result of  a  sexually  transmitted
disease.  Other causes are mis.rriage  and delivery in conditions of inadequate health care, and  illegal abortion.
2  HRP's ow'n research on RU-486, a substance which has attracted some controversy, accounts for 1.8% of the
total HRP budget.9
The  causes  in men  are  less  well  understood.  HRP  has  recently  started a  multinational project  to study  the
prevalence  of past  chiamydial  and gonococcal  diseases  as a cause  of male and temrnle  n..ertility. It is also  promoting
the development of a simple diagnostic kit for chiamydial infection, testing new and established barrier methods for
the prevention of reinfection with STDs,  and testing drugs effective in preventing transmission.  In addition,  it is
supporting preliminary studies on the development of a vaccine against chlamydial infection.
17.  Behavioral and Social ePactors. HRP was one of the first, and remains one of the few, orgarizations  to conduct
research into the behavioral and social determinants of fertility regulation, exploring the attributes of methods that
make them acceptable to users,  and the processes by which users select, adopt and continue contraceptive use over
time.  Its studies have demonstrated  the importance of  providing a  range of  methods among  which  clients can
choose, of counselling, ai.. of continued contact between provider and client--all aspects of what have come to be
called the  "user-perspective".  As  the programme  becomes increasingly involved with  the  introduction of  new
methods into family planning programs,  such research  becomes even more important.
18.  Contraceptive  Introduction.  The  introduction of  the  new contraceptive  implant,  NORPLANT,  is a  good
example of HRP's  involvement in the field.  Once the contraceptive was developed by the Population Council, HRP
coordinated with the Council and with Family Health International on its limited introduction in many countries and
in post-marketing surveillance.  A 20-center cohort study in 10 countries has been initiated to determine the medium-
and  long-term  bei.efits or  problems  of  NORPLANT  use.  No  contraceptive  compound  has  ever  before  been
introduced with such care.
Resources  for Research
19.  HRP helps national authorities and institutions in de  'eloping  countries to establish research infrastructure in
the area of reproductive health,  giving priority to developing epidemiological and social science capability.  The10
program concentrates  its activities  on a selected  number  of countries  in  which it can make  a significant  contribution.
As institutions  become more self-reliant,  core support is gradually  withdrawn  and transferred to other countries,
but many  of the 'graduate' organizations  compete  successfully  not only  for funding  from the lask Forces, but froia
other agencies  engaged  in reproductive  research. The original focus  of the program was on individual  institutions,
but has recently shifted to building  national capacity  with the objective  of identifying,  and finding solutions  to,
locally  prevalent  problems in the broad field of reproductive  health.
20.  The Committee on Resources for Research makes recommendations  on how to improve the developing
countries' research resources.  The main instr  iment for research-capability  strengthening  is the Long-Term
Institutional  Development Grant.  This type of grant covers several dimensions  of institutional  development:
technical  assistance  in the drawing  up of a nationally  relevant  research  program,  strengthening  of material  resources,
and developing  human resources through Research -raining Grants to individual  scientists.  Since 1986, 38
institutions  in 29 developing  countries  have received  long-term  institutional  development  grants.  Other grants  are
available to support scientists after their training abroad, to purchase equipment and supplies, to hold training
courses and workshops,  establish  postgraduate  degree programs  and provide  visits for exchange  of experience.
21.  Recently  HRP carried out a survey of scientists  and supporting  staff  who had received  Research  Training  and
Visiting  Scientist Grants between the start of the program in 1972 and the year 1987.  There were 954 such
grantees, of whom  855 came from developing  countries. The encouraging  finding  was that  two-thirds  of those for
whom information  was obtained  (84%)  were still engaged  in research.
FINANCIAL  SUPPORT  FOR HRP
22.  Over the years HRP has attracted  funds of well over $250 rnillion. Table 1 shows  the level of funding  since
its inception. (HRP became  a Special Programme  in 1972, but there was a pre-existing  WHO program.) In the
first two years of Bank financial support for the program, 23  governments  and agencies (including WHO)11
Table 1:  Income for 1988-1989  and for the period 1970 to 1989  (in US$ thousands)
[  Source  of funds  1988  1989  1970-1989
Australia  160.3  185.1  1,513.1
Bangladesh  5.0  5.0
Canada  *  3,401.9
China  50.0  50.0  400.0
Cuba  4.0  22.6
Denmark  2,268.3  2,083.4  19,211.0
Famnily  Health International  (USA)  . 20S.0  205.0
Finland  230.5  251.3  1,797.8
Ford Foundation (USA)  . 1,000.0
France  6.5
Germany, Fed. Rep. of  1,339.4  719.4  6,288.1
IDRC (Canada)  233.9  302.2  516.5
India  79.3  456.0
Italy  . 259.8
Kenya  0.5
Malaysia  1.1
Mexico  3.0  3.0  66.0
Netherlands  392.7  343.6  2,407.7
Nigeria  51.2
Norway  1,923.1  1,965.1  32,736.6
Pakistan  5.0
Rockefeller  Foundation  (USA)  . 350.0  1,050.0
Sweden  2,548.2  2,280.7  80,692.5
Switzerland  283.3  . 577.5
Thailand  7.5  15.0  71.6
United Kingdom  5,966.5  3,573.7  34,838.1
United States of America  . 3,220.6
USSR  (in kind)  46.3  46.3
UNDP  . 56.5  56.5
UNFPA  3,250.0  3,500.0  27,040.0
WHO  75.0
World Bank  3,000.0  2,000.0  5,008.3
Miscellaneous  33.3  1.0  36.0
Interest  449.0  661.3  9,412.4
Handling  change for reagents  128.4  157.1  719.0
Patents  68.9
Sub-total  22,318.7  18,687.7  238,269.1
WHO Regular Budget  and Special  Account  649.1  649.1  8,825.0
UNFPA funds for country and inter-country
projects  1,526.1  1,397.8  17,063.6
Total income  24,493.9*  20,734.6  264,157.7
O  of which $21,434.0 relates  to 1988  and $3,059.9 to 1987. The lattci amount  consists  of two 1987  pledged
contributions  ($2,059,925  from the United  Kingdom  and $1.0 million  from the World Bank)  which  arrived at
the beginning  of 1988  and therefore  had to be taken  up as 1988  income in WHO's Financial  Report.
Source: See Fig. 1.12
contributed,  of which 6 were developing-country governments.  The major bilateral donors are the U.K.,  Sweden,
Denmark, Norway and Germany.  The Bank's contribution provides general support to the program,  whose outlays
1986-1989 are shown  in Table 2.  In FY89 and  in FY90 the Bank contributed a further  $1  million to WIHO to
support activities for AIDS research.  Of this, $665,000 was used to finance activities agreed between the Global
Program on AIDS (GPA) and HRP, and $335,000 went to activities agreed between GPA and TDR.  The Bank's
financial support  of  HRP,  part of  the  Special Grants  Program,  is administered  by the  Population  and  Human
Resources Department  of PRE.
Table 2:  Obligations during the biennia 1988-1989 and  1986-1987 by
Programme Area (in US$ thousands)
1986-1987  I  1988-1989
Programme  Area  Obligations  %  Obligations  %
Advisory Bodies  272  0.7  471  1.1
Research and Development  18,169  50.2  22,104  51.0
Resources for Research  9,332  25.8  10,836  25.0
Statistics and Data Processing  2,143  5.9  2,348  5.4
Programme Management  2,997  8.3  3,922  9.1
Collaborative  Projects  183  0.5  745  1.7
UNFPA  Country projects  3,119  8.6  2,924  6.7
Tntql  36,215*  100.0  43.350  100.0
*  A sum of US$1,882,000  relating to Research and Development and Resources for Research was obligated
only in early January  1988 due to the late arrival of two contributions pledged for 1987 (see footnote* on Table
1).  This amount has been included under  1986-1987 in this table and in Table 3 to avoid distorting the trend of
obligations.
EXTERNAL  EVALUATIONS
23.  Three  major external evaluations of HRP have been undertaken.  The most recent took place in 1986 - 1988,
and focused on HRP's impact,  especially  in developing  countries. The Report concludes: 'The Evaluation  Team13
is very positive towards the work of HRP  and recognizes that the Programme has had a major impact.  Indeed it
has been the principal, if not the lone impact in many areas, e.g.  the developent of new fertility regulation methods
and its unique role of coordination of research efforts on a global scale.'  The Evaluation Report firmlv recommends
that HRP  continue as a  Special Programme within the U.N.  system.  Recent reports  from  two highly regarded
bodies--the Conunission on  Health Research for Development,  and  a Committee of  the U.S.  National  Research
Council and the Institute of  Medicine--gave the HRP strong endorsement.
ROLE OF THE  BANK
24.  The Bank's co-sponsorship of HRP has strengthened the program's  links with governments and  facilitated its
access  to  ministries  outside  the  health  field.  The  Bank's  role  is  considered  important  in  assisting  policy
coordination,  and in helping to sustain donor commitment to the program.  The Bank's contribution of $2 million
a year represents 10% of HRP's total funding.  Bank staff have played an active part on the Policy and Coordination
Commnittee,  the  Standing Committee,  and  in the  Behavioral and  Social  Determinants  Task  Force.  Its  policy,
management, and technical advice and expertise have been important in providing program direction.  The work
of  the  program  in developing new technology,  establishing the safety and  effectiveness of  existing technology,
studying  broad areas of  reproductive health  cencern--infertility,  maternal health, and  AIDS-and  supporting the
development of national research capacity complements the population and health .vork of the Bn  imny  --ays.
HRP has gained intemational respect, and by its solid record of achievement has justified  the expectations placed
on it when it became a co-sponsored program two years ago.  It merits continued and expanded Bank support.PRE  Workina  Paper  Series
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